Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danhong Huayu oral solution is a Traditional Chinese Medicine (TCM) therapeutic developed by the Beijing Hospital of Traditional Chinese Medicine, specifically for the treatment of retinal vein occlusion (RVO). The formulation is based on the therapeutic principles of activating blood and resolving stasis (Huayu) and clearing heat and cooling blood. It is designed to improve ocular microcirculation, inhibit platelet aggregation, and facilitate the resolution of retinal hemorrhages and edema. As a hospital-developed preparation, it has been evaluated in clinical trials to assess its efficacy in improving visual acuity and reducing retinal thickness in patients suffering from various forms of RVO.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Danhong Huayu oral solution.